[1] Parkin DM,Bray F. Evaluation of data quality in the cancer registry: principles and methods. Part Ⅱ. Completeness[J]. Eur J Cancer,2009,45:756-764. [2] 冯庆来,尚淑艳,赵锡江.胸段食管癌淋巴结转移规律的探讨[J].中国肿瘤临床,2005,32:706-708. [3] Kato H,Tachimori Y,Watanabe H,et al.Lymph node metastasis in thoracic esophageal carcinoma[J].J Surg Oncol,1991,48:106-111. [4] Lerut T,Nafteux P,Moons J,el a1.Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging,diseasefree survival,and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma[J].Ann Surg,2004,240:962-972. [5] Nakamura T,Hatooka S,Kodaira T,et al. Determination of the irradiation field for clinical T1-3N0M0 thoracic/abdominal esophageal cancer based on the postoperative pathological results[J].Jpn J Clin Oncol,2009,39:86-91. [6] Huang W,Li BS,Gong HY,et al. Pattern of lymph node metastases and its implication in radiotherapeutic clinical target volume in patients with thoracic esophageal squamous cell carcinoma: a report of 1077 cases[J]. Radiother Oncol,2010,95:229-233. [7] Igaki H,Tachimori Y,Kato H,et al. Improved survival for patients with upper and/or middle mediastinal lymph node metastasis of squamons cell carcinoma of the lower thoracic esophagus treated with 3-field dissection[J].Ann Surg,2004,239:483-490. [8] Mitsuo T,Shoichi K,Hiroshi Y,et al. Clinical outcomes of extended esophagectomy with three-field lymph node dissection for esophageal squamous cell carcinoma[J]. Am J Surg,2005,189:98-109. [9] 宁国庆,袁宪顺,吕守臣,等.螺旋CT增强扫描对食管癌淋巴结转移的诊断价值[J].医学影像学杂志,2007,17:148-151. [10] 郭洪波,于金明,张百江,等.氟脱氧葡萄糖PET-CT确定食管癌淋巴结放疗靶区的可行性研究[J].中华放射肿瘤学杂志,2007,16:10-14. [11] Yuan S,Yu Y,Chao KS,et al. Additional value of PET-CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer[J].J Nucl Med,2006,47:1255-1259. [12] Cooper JS,Guo MD,Herskovic A,et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial(RTOG-85-01)[J].JAMA,1999,281:1623-1627. [13] Minsky BD,Pajak TF,Ginsberg RJ,et al.INT0123(Radiation Therapy Oncology Group 94-05)phase Ⅲ trial of combined-modality therapy for esophageal cancer:high-dose versus standard-dose radiation therapy[J].J Clin Oncol,2002,20:1167-1174. [14] Ishikura S,Nihei K,Ohtsu A,et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus[J].J Clin Oncol,2003,21:2697-2702. [15] Onozawa M,Nihei K,Ishikura S,et al. Elective nodal irradiation(ENI)in definitive chemoradiotherapy(CRT) for squamous cell carcinoma of the thoracic esophagus[J].Radiother Oncol,2009,92:266-269. [16] Yamashita H,Okuma K,Wakui R,et al. Detail of recurrence sites after elective nodal irradiatioin(ENI) using 3D-conformal radiotherpapy(3DCRT) combined with chemotherapy for thoracic esophageal squamous cell carcinoma-a retrospective analysis[J]. Radiother Oncol,2011,98:255-260. [17] Kato K,Nakajima TE,Ito Y,et al. Phase Ⅱ study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for stage Ⅱ-Ⅲ esophageal carcinoma[J].Jpn J Clin Oncol,2013,43:608-615. [18] 杨哲,颜廷秀,洪士强,等.食管癌三维适形放疗疗效和靶区勾画与局部复发关系的探讨[J].中华肿瘤防治杂志,2008,15:939-942. [19] 陈刚,杨昊.分析食管癌根治性放疗后复发模式确定是否选择性淋巴结照射[J].疾病监测与控制杂志,2010,4:615-616. [20] Li BS,Zhou T,Wang ZT,et al. Phase Ⅰ study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and Capecitabine,Cisplatin for locally advanced esophageal squamous cell carcinoma[J]. Radiother Oncol,2009,93:458-461. [21] Wang D,Yang J,Zhu J,et al. Elective lymph node irradiation late course accelerated hyper-fractionated radiotherapy plus concurrent cisplatin-based chemotherapy for esophageal squamous cell carcinoma: a phase Ⅱ study[J/OL].Radiat Oncol,2013,8:108[2013-12-20].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653710/. [22] Wang D,Yang J,Zhu J,et al.3D-conformal RT,fixed-field IMRT and RapidArc,which one is better for esophageal carcinoma treated with elective nodal irradiation[J]. Technol Cancer Res Treat,2011,10:487-494. [23] Kawaguchi Y,Nishiyama K,Miyagi K,et al. Patterns of failure associated with involved field radiotherapy in patients with clinical stage Ⅰ thoracic esophageal cancer[J].Jpn J Clin Oncol,2011,41:1007-1012. [24] Button MR,Morgan CA,Croydon ES,et al. Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy[J].Int J Radiat Oncol Biol Phys,2009,73:818-823. [25] Ji K,Zhao L,Yang C,et al. Three-dimensional conformal radiation for esophageal squamous cell carcinoma with involved-field irradiation may deliver considerable doses of incidental nodal irradiation[J/OL].Radiat Oncol,2012,7:200[2013-12-20]. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585467/. [26] Zhao KL,Ma JB,Liu G,et al. Three-dimensional conformal radiation therapy for esophageal squamous cell carcinoma: is elective nodal irradiation necessary?[J]. Int J Radiat Oncol Biol Phys,2010,76:446-451. [27] 张萍,谢聪颖,吴式琇.紫杉醇联合铂类与放疗同步治疗局部晚期食管癌的临床研究[J].中华肿瘤杂志,2007,29:773-777. [28] 周超,杨海华,胡炜,等.局部晚期食管癌扩大野同期放化疗的临床研究[J].中华放射肿瘤学杂志,2012,21:522-525. [29] 易金玲,张萍,谢聪颖,等.食管癌扩大照射野放射治疗的剂量学研究[J].中国医学物理学杂志,2009,26:1395-1398. [30] 李曼,乔学英,周志国,等.胸段食管癌三维适形放疗临床靶体积前瞻性随机临床研究[J].中国肿瘤临床,2012,39:1294-1298. [31] 周志国,乔学英,高献书,等.食管癌三维适形放疗临床靶体积研究[J].中华放射肿瘤学杂志,2009,18:86-87. [32] 舒中琴,于波,顾小伟,等.食管癌三维适形放疗不同靶区勾画的临床观察[J].实用临床医药杂志,2010,14:146-147. [33] 李多杰,李红伟,何斌,等.食管癌适形调强放疗累及野和扩大野的比较研究[J].中国肿瘤临床,2013,20:1248-1251. [34] Ma JB,Song YP,Yu JM,et al. Feasibility of involved-field conformal radiotherapy for cervical and upper-thoracic esophageal cancer[J].Onkologie,2011,34:599-604. [35] 祝淑钗,许金蕊,刘志坤,等.三维技术放疗食管癌不同临床靶区的初步研究[J].中华放射肿瘤学杂志,2014,23:127-111.
2014, Vol. 23 
